AIMNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AIM ImmunoTech Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$0.16−0.01 (-2.97%)
Close on Oct 19, 2026
- Market cap
- $2.79M
- P/E (TTM)
- –
- Dividend yield
- –
AIM ImmunoTech Inc. revenue by segment
By business segment
By product or service
| Revenue | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Clinical Treatment Programs - US [Member] | $141.00K | $135.00K | $144.00K | – | 100.0% | +4.4% |
| Clinical Treatment Programs - Europe [Member] | – | – | $19.00K | – | – | – |
By region
| Revenue | FY2022 | FY2021 | FY2020 | FY2019 | % of revenue | YoY |
|---|---|---|---|---|---|---|
| Europe [Member] | – | – | $19.00K | $30.00K | – | – |
| US [Member] | – | – | $144.00K | $110.00K | – | – |
From the segment and revenue-disaggregation notes of AIM ImmunoTech's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.